InicioSGEN • BMV
add
Seagen
Cierre anterior
3711,48 $
Intervalo anual
3711,48 $ - 3711,48 $
Cap. bursátil
43,15 mil M USD
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Noticias sobre los mercados
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
(USD) | sept 2023info | Cambio interanual |
---|---|---|
Ingresos | 648,65 M | 27,11 % |
Gastos operativos | 262,69 M | 24,86 % |
Ingresos netos | -215,79 M | -13,09 % |
Margen de beneficio neto | -33,27 | 11,02 % |
Beneficios por acción | -1,15 | -11,65 % |
EBITDA | -209,33 M | -19,47 % |
Tipo impositivo efectivo | 0,26 % | — |
Balance general
Activos totales
Responsabilidades totales
(USD) | sept 2023info | Cambio interanual |
---|---|---|
Efectivo y a corto plazo | 1236,99 M | -29,86 % |
Activos totales | 3634,26 M | 0,42 % |
Responsabilidades totales | 1083,84 M | 35,94 % |
Patrimonio total | 2550,42 M | — |
Acciones en circulación | 188,66 M | — |
Precio-valor contable | 274,52 | — |
Rentabilidad económica | -16,01 % | — |
Retorno sobre capital | -21,12 % | — |
Flujo de caja
Variación neta del flujo de caja
(USD) | sept 2023info | Cambio interanual |
---|---|---|
Ingresos netos | -215,79 M | -13,09 % |
Efectivo de operaciones | -35,82 M | 58,21 % |
Efectivo de inversión | 142,49 M | 119,31 % |
Efectivo de financiación | 15,52 M | -15,59 % |
Variación neta del flujo de caja | 119,90 M | 1.958,05 % |
Flujo de caja libre | 71,52 M | 1.141,10 % |
Información sobre la empresa
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The company's flagship product Adcetris is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program
to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Wikipedia
Director ejecutivo
Fundación
15 jul 1997
Sitio web
Empleados
3.256